TKI-话题@MedSci

#TKI#

128篇内容 | 3899人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1384223, encodeId=0485138422366, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=EGFR-TKIs药物相关口腔炎病例报告, objectType=article, longId=195842, objectId=3250195842c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3250195842c6, replyNumber=0, likeNumber=0, createdTime=2020-06-15, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3250195842c6, moduleTitle=EGFR-TKIs药物相关口腔炎病例报告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3250195842c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384222, encodeId=683b13842226a, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=FDA授予亚盛医药的第三代TKI抑制剂HQP1351孤儿药指定，用于治疗慢性粒细胞白血病, objectType=article, longId=193620, objectId=85f31936203d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85f31936203d, replyNumber=0, likeNumber=88, createdTime=2020-05-08, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85f31936203d, moduleTitle=FDA授予亚盛医药的第三代TKI抑制剂HQP1351孤儿药指定，用于治疗慢性粒细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85f31936203d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384221, encodeId=6d0b138422193, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=姚煜教授：抗血管生成单抗联合TKI治疗有望成为EGFR 21L858R突变晚期NSCLC治疗金标准, objectType=article, longId=191912, objectId=afff191912f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afff191912f3, replyNumber=0, likeNumber=74, createdTime=2020-04-11, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afff191912f3, moduleTitle=姚煜教授：抗血管生成单抗联合TKI治疗有望成为EGFR 21L858R突变晚期NSCLC治疗金标准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afff191912f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384220, encodeId=c01e13842208e, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=欧盟批准武田的TKI抑制剂ALUNBRIG，用作ALK阳性非小细胞肺癌患者的一线治疗药物, objectType=article, longId=191689, objectId=a505191689b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a505191689b3, replyNumber=0, likeNumber=71, createdTime=2020-04-09, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a505191689b3, moduleTitle=欧盟批准武田的TKI抑制剂ALUNBRIG，用作ALK阳性非小细胞肺癌患者的一线治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a505191689b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384219, encodeId=cae51384219a4, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=豪森药业第三代EGFR TKI在中国获批用于EGFR T790M突变型非小细胞肺癌的二线治疗, objectType=article, longId=190514, objectId=8e2119051451, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e2119051451, replyNumber=0, likeNumber=96, createdTime=2020-03-22, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e2119051451, moduleTitle=豪森药业第三代EGFR TKI在中国获批用于EGFR T790M突变型非小细胞肺癌的二线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e2119051451)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384218, encodeId=08da1384218d6, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Sci Rep：EGFR-TKIs治疗EGFR突变型非小细胞肺癌的神经生长因子表达及其临床意义, objectType=article, longId=185036, objectId=79b218503619, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79b218503619, replyNumber=0, likeNumber=92, createdTime=2019-12-23, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79b218503619, moduleTitle=Sci Rep：EGFR-TKIs治疗EGFR突变型非小细胞肺癌的神经生长因子表达及其临床意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=79b218503619)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384217, encodeId=9925138421e9f, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=由细入微，多靶点TKI安罗替尼促软组织肉瘤疗效升级！, objectType=article, longId=184329, objectId=031b184329f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=031b184329f9, replyNumber=0, likeNumber=75, createdTime=2019-12-08, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=031b184329f9, moduleTitle=由细入微，多靶点TKI安罗替尼促软组织肉瘤疗效升级！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=031b184329f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384216, encodeId=e9de138421680, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=NSCLC术后复发转移的诊疗仍有难点，三代EGFR-TKI或可助力突破现状, objectType=article, longId=184136, objectId=38471841368e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38471841368e, replyNumber=0, likeNumber=63, createdTime=2019-12-05, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38471841368e, moduleTitle=NSCLC术后复发转移的诊疗仍有难点，三代EGFR-TKI或可助力突破现状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=38471841368e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384215, encodeId=231b138421577, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=JAMA Oncol：EGFR-TKIs治疗联合二甲双胍可明显改善晚期肺腺癌患者的PFS, objectType=article, longId=183104, objectId=0beb18310413, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0beb18310413, replyNumber=0, likeNumber=93, createdTime=2019-11-19, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0beb18310413, moduleTitle=JAMA Oncol：EGFR-TKIs治疗联合二甲双胍可明显改善晚期肺腺癌患者的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0beb18310413)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384214, encodeId=bdb81384214d4, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=2019 ESMO |TKI治疗论坛：中外大咖台论道，引领肠癌、肝癌治疗新理念, objectType=article, longId=180454, objectId=2c23180454c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c23180454c6, replyNumber=0, likeNumber=68, createdTime=2019-10-05, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c23180454c6, moduleTitle=2019 ESMO |TKI治疗论坛：中外大咖台论道，引领肠癌、肝癌治疗新理念, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c23180454c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384213, encodeId=67ba13842136b, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=梁乃新教授：NSCLC术后复发/转移的治疗经验分享，精准检测和第三代TKI至关重要, objectType=article, longId=180147, objectId=dde318014e1e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dde318014e1e, replyNumber=0, likeNumber=83, createdTime=2019-09-29, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dde318014e1e, moduleTitle=梁乃新教授：NSCLC术后复发/转移的治疗经验分享，精准检测和第三代TKI至关重要, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dde318014e1e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384212, encodeId=0c7d13842121c, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=系统比较**、二、三代EGFR-TKI，综合实力奥希替尼更胜一筹, objectType=article, longId=178672, objectId=fd2a1e867284, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd2a1e867284, replyNumber=0, likeNumber=79, createdTime=2019-09-04, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd2a1e867284, moduleTitle=系统比较**、二、三代EGFR-TKI，综合实力奥希替尼更胜一筹, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd2a1e867284)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384211, encodeId=48f3138421161, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=“三代同堂”谁领风骚？EGFR-TKI一线疗效和安全性大比拼, objectType=article, longId=176915, objectId=b5e21e691585, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5e21e691585, replyNumber=0, likeNumber=65, createdTime=2019-08-06, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5e21e691585, moduleTitle=“三代同堂”谁领风骚？EGFR-TKI一线疗效和安全性大比拼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5e21e691585)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384210, encodeId=ff5f13842100e, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=EGFR敏感突变晚期NSCLC患者的TKI治疗策略, objectType=article, longId=175265, objectId=8f8b1e5265b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f8b1e5265b4, replyNumber=0, likeNumber=81, createdTime=2019-07-13, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f8b1e5265b4, moduleTitle=EGFR敏感突变晚期NSCLC患者的TKI治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f8b1e5265b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384209, encodeId=cf0c138420972, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=宋勇教授：如何驾驭EGFR TKI三匹宝马？, objectType=article, longId=169067, objectId=589e16906e20, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=589e16906e20, replyNumber=0, likeNumber=66, createdTime=2019-06-26, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=589e16906e20, moduleTitle=宋勇教授：如何驾驭EGFR TKI三匹宝马？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=589e16906e20)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384208, encodeId=5a861384208f5, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=吴一龙教授：从奥希替尼联合抗血管生成看EGFR-TKI耐药问题的解决, objectType=article, longId=168217, objectId=b3e216821e12, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3e216821e12, replyNumber=0, likeNumber=100, createdTime=2019-06-14, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3e216821e12, moduleTitle=吴一龙教授：从奥希替尼联合抗血管生成看EGFR-TKI耐药问题的解决, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3e216821e12)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384207, encodeId=b72d138420ee1, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=安全性和有效性双管齐下 ——关注EGFR-TKI肝毒性聚焦药物相互作用, objectType=article, longId=168149, objectId=6885168149ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6885168149ba, replyNumber=0, likeNumber=78, createdTime=2019-06-13, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6885168149ba, moduleTitle=安全性和有效性双管齐下 ——关注EGFR-TKI肝毒性聚焦药物相互作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6885168149ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384206, encodeId=08a11384206ce, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=从奥希替尼联合抗血管生成看EGFR-TKI耐药问题的解决, objectType=article, longId=168100, objectId=14f816810048, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14f816810048, replyNumber=0, likeNumber=83, createdTime=2019-06-12, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14f816810048, moduleTitle=从奥希替尼联合抗血管生成看EGFR-TKI耐药问题的解决, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14f816810048)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384205, encodeId=92c013842055d, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=研究分析:血浆EGFR突变早期清除预测EGFR-TKI疗效, objectType=article, longId=167952, objectId=6ae716e9520e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ae716e9520e, replyNumber=0, likeNumber=61, createdTime=2019-06-11, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ae716e9520e, moduleTitle=研究分析:血浆EGFR突变早期清除预测EGFR-TKI疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ae716e9520e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384204, encodeId=1903138420463, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=ASCO2019 |化疗优于EGFR TKI？中国晚期NSCLC EGFR 20外显子插入突变患者的真实世界治疗结果, objectType=article, longId=167660, objectId=579916e66023, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=579916e66023, replyNumber=0, likeNumber=0, createdTime=2019-06-06, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=579916e66023, moduleTitle=ASCO2019 |化疗优于EGFR TKI？中国晚期NSCLC EGFR 20外显子插入突变患者的真实世界治疗结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=579916e66023)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

TKI

2020-05-29

lsj628 (审核中...)

前往app查看评论内容

#TKI#

EGFR-TKIs药物相关口腔炎病例报告

2020-06-15

lsj628 (审核中...)

前往app查看评论内容

#TKI#

FDA授予亚盛医药的第三代TKI抑制剂HQP1351孤儿药指定，用于治疗慢性粒细胞白血病

2020-05-08

lsj628 (审核中...)

前往app查看评论内容

#TKI#

姚煜教授：抗血管生成单抗联合TKI治疗有望成为EGFR 21L858R突变晚期NSCLC治疗金标准

2020-04-11

lsj628 (审核中...)

前往app查看评论内容

#TKI#

欧盟批准武田的TKI抑制剂ALUNBRIG，用作ALK阳性非小细胞肺癌患者的一线治疗药物

2020-04-09

lsj628 (审核中...)

前往app查看评论内容

#TKI#

豪森药业第三代EGFR TKI在中国获批用于EGFR T790M突变型非小细胞肺癌的二线治疗

2020-03-22

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Sci Rep：EGFR-TKIs治疗EGFR突变型非小细胞肺癌的神经生长因子表达及其临床意义

2019-12-23

lsj628 (审核中...)

前往app查看评论内容

#TKI#

由细入微，多靶点TKI安罗替尼促软组织肉瘤疗效升级！

2019-12-08

lsj628 (审核中...)

前往app查看评论内容

#TKI#

NSCLC术后复发转移的诊疗仍有难点，三代EGFR-TKI或可助力突破现状

2019-12-05

lsj628 (审核中...)

前往app查看评论内容

#TKI#

JAMA Oncol：EGFR-TKIs治疗联合二甲双胍可明显改善晚期肺腺癌患者的PFS

2019-11-19

lsj628 (审核中...)

前往app查看评论内容

#TKI#

2019 ESMO |TKI治疗论坛：中外大咖台论道，引领肠癌、肝癌治疗新理念

2019-10-05

lsj628 (审核中...)

前往app查看评论内容

#TKI#

梁乃新教授：NSCLC术后复发/转移的治疗经验分享，精准检测和第三代TKI至关重要

2019-09-29

lsj628 (审核中...)

前往app查看评论内容

#TKI#

系统比较**、二、三代EGFR-TKI，综合实力奥希替尼更胜一筹

2019-09-04

lsj628 (审核中...)

前往app查看评论内容

#TKI#

“三代同堂”谁领风骚？EGFR-TKI一线疗效和安全性大比拼

2019-08-06

lsj628 (审核中...)

前往app查看评论内容

#TKI#

EGFR敏感突变晚期NSCLC患者的TKI治疗策略

2019-07-13

lsj628 (审核中...)

前往app查看评论内容

#TKI#

宋勇教授：如何驾驭EGFR TKI三匹宝马？

2019-06-26

lsj628 (审核中...)

前往app查看评论内容

#TKI#

吴一龙教授：从奥希替尼联合抗血管生成看EGFR-TKI耐药问题的解决

2019-06-14

lsj628 (审核中...)

前往app查看评论内容

#TKI#

安全性和有效性双管齐下 ——关注EGFR-TKI肝毒性聚焦药物相互作用

2019-06-13

lsj628 (审核中...)

前往app查看评论内容

#TKI#

从奥希替尼联合抗血管生成看EGFR-TKI耐药问题的解决

2019-06-12

lsj628 (审核中...)

前往app查看评论内容

#TKI#

研究分析:血浆EGFR突变早期清除预测EGFR-TKI疗效

2019-06-11

lsj628 (审核中...)

前往app查看评论内容

#TKI#

ASCO2019 |化疗优于EGFR TKI？中国晚期NSCLC EGFR 20外显子插入突变患者的真实世界治疗结果

2019-06-06

科室
- - 订阅+
  - 更多科室
工具
服务